[Pharmacokinetics of fluoropyrimidines].
Pharmacokinetic behaviors of 5-FU and masked fluoropyrimidines were reviewed. Anabolic and catabolic pathways of 5-FU Pharmacokinetics of 5-FU-blood level, absorption, drug interaction Tegafur (FT)-blood level, absorption, activation to 5-FU by P-450 UFT-high 5-FU level in tissues, especially in tumor tissues, by inhibiting the catabolism of 5-FU from FT with uracil HCFU-relatively high 5-FU production, independent of the liver, high drug distribution in cancerous ascites 5'-DFUR-activation to 5-FU by uridine- or thymidine- phosphorylase, high 5-FU level in tumor tissues
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D005472:Fluorouracil / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011817:Rabbits; D005641:Tegafur / Q000378:metabolism; D014498:Uracil / Q000378:metabolism
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil